



# The Study Start-Up Process

Presented by Emily Cox, PhD

10:50pm-11:50pm  
UW Husky Union Building



Institute of *Translational* Health Sciences  
ACCELERATING RESEARCH. IMPROVING HEALTH.

**The study start-up process**  
Navigating the sequence and timing of reviews,  
approvals, and resources before your study  
starts

Emily Cox, PhD, ACSM CEP  
Project Manager/Scientific Publication Writer  
Providence Medical Research Center

# Today's topics



- How to navigate extramural research
  - Federally funded trials
  - Industry-funded trials
- How to analyze failures and initiate process improvements
- Objective
  - Understand infrastructure maturity requirements for clinical research
  - Understand the general pathway for study start-up
  - Know how to conduct an after-action review

**Writing  
Grant submission  
Funding**

**Start-up**




# “Why does start-up take so long?”


- Slow CRO responses
- Legal or compliance questions
- Sponsor acquisition
- Inexperienced sponsor team
- New hardware
- New software
- Contracting with 3<sup>rd</sup> party suppliers
- Staff PTO
- Insufficient feasibility assessment
- Regulatory disagreements
- Medical device purchasing
- Lack of subject injury protection
- Investigator loss of interest
- IRB turnaround times
- Staff turnover
- Changes in workload
- Protocol amendments
- Unexpected study closure
- Budget stalemate
- Change of clinic location
- Pharmacy issues




# Project management constraints



# Project management constraints




# Project management constraints



Quick  
High quality  
**Costly**



# Project management constraints



# Project management constraints

## *Clinical Trial Space*

Low cost  
High quality  
**Slow**


Quality

Quick  
High quality  
**Costly**

Cost

Time

Quick, Low cost, **Low quality**



# Quality is federally mandated and highly regulated

## NIH clinical trials

- Yes to all:
  - Does the study involve human participants?
  - Are the participants prospectively assigned to an intervention?
    - An intervention is defined as a manipulation of the subject or subject's environment for the purpose of modifying one or more health-related biomedical or behavioral processes and/or endpoints. Examples include: drugs/small molecules/compounds; biologics; devices; procedures (e.g., surgical techniques); delivery systems (e.g., telemedicine, face-to-face interviews); strategies to change health-related behavior (e.g., diet, cognitive therapy, exercise, development of new habits); treatment strategies; prevention strategies; and, diagnostic strategies.
  - Is the study designed to evaluate the effect of the intervention on the participants?
  - Is the effect being evaluated a health-related biomedical or behavioral outcome?


## FDA investigations

- 21 CFR 312
  - Any experiment in which a drug is administered or dispensed to, or used involving, one or more human subjects. For the purposes of this part, an experiment is any use of a drug except for the use of a marketed drug in the course of medical practice.
- Do you need an IND?
  - Exemptions given in 21 CFR 312.2
- 21 CFR 812
  - A clinical investigation or research involving one or more subjects to determine the safety or effectiveness of a device

# Infrastructure maturity in clinical research

	Grant prime award	Grant sub-award	FDA-regulated trials	Unfunded intramural study
Standard start-up process	✓	✓	✓	✓
Multi-site coordination	✓			
Federal grants management	✓	✓		
Contract negotiation	?	?	✓	
Clinical trial budgeting	?	?	✓	
FDA inspection management	?	?	✓	
Patient recruitment	✓	✓	✓	✓
Clinical processing/labs	?	?	✓	
Storing and handling data	✓	✓	✓	✓
IRB review	✓	✓	✓	✓
Essential document management	✓	✓	✓	✓

# Funding types and research pathways




Conduct a  
federally-  
funded  
study

Prime award

Sub-award



Participate  
in a  
federally-  
funded  
study



Be a site  
in an  
industry  
trial

FDA-regulated

# Funding types and research pathways



Conduct a  
federally-  
funded  
study

Prime award

Sub-award

Participate  
in a  
federally-  
funded  
study

Be a site  
in an  
industry  
trial

FDA-regulated

# Responsibilities of sponsors and invest




## Sponsor

- Complies with

- 21 CFR 312.50



- 21 CFR 812 subpart C




## Investigator

- Complies with

- 21 CFR 312.60




- 21 CFR 812 subpart E




# FDA-regulated clinical trial start-up


- Study start-up is a mutual evaluation between the sponsor and the site
- Feasibility is crucial







# Funding types and research pathways




Conduct a  
federally-  
funded  
study

Prime award

Sub-award




Participate  
in a  
federally-  
funded  
study



Be a site  
in an  
industry  
trial

FDA-regulated



# How will I...

- Do I need an IND or IDE?
- Ensure every site can handle federal awards?
- Organize contact information and track staff changes?
- Coordinate IRB reliance agreements and approvals?
  - Now, must include single IRB plan in grant applications
  - Changes who can include IRB fees in indirect costs (NIH NOT-OD-16-109)
- Coordinate budgets?
- Plan recruitment?
- Negotiate subaward terms?
- Communicate amendments?
- Collect data?
- Manage protocol deviations?

# Funding types and research pathways

Conduct a  
federally-  
funded  
study


Prime award

Sub-award

Participate  
in a  
federally-  
funded  
study

Be a site  
in an  
industry  
trial

FDA-regulated



# Common pitfalls for PIs



- Make sure you can start all four pathways at once
  - Send start-up documents for all four pathways
- Plan for extramural process and policy differences
  - Common cause for delay
  - Know the difference between a protocol and a manual of procedures
- Have a plan for site communication
- Plan your electronic data capture (EDC) system
- Have clear-cut and modern recruitment plans

# Changing perspectives on start-up “delays”



Cost of planning



Cost of mistakes



# Continuous process improvement



# “Why does start-up take so long?”

- Slow CRO responses
- Legal or compliance questions
- Sponsor acquisition
- Inexperienced sponsor team
- New hardware
- New software
- Contracting with 3<sup>rd</sup> party suppliers
- Staff PTO
- Insufficient feasibility assessment
- Regulatory disagreements
- Medical device purchasing
- Lack of subject injury protection
- Investigator loss of interest
- IRB turnaround times
- Staff turnover
- Changes in workload
- Protocol amendments
- Unexpected study closure
- Budget stalemate
- Change of clinic location
- Pharmacy issues



# The TERRIBLE Trial\*

## WHAT WAS SUPPOSED TO HAPPEN



**Open in 90 days**  
**Enroll 3 participants in 180 days**

### •The TERRIBLE Trial

- ▶ Investigational new drug
- ▶ Eligible patients have a rare genotype and are treatment naïve
- ▶ Standard of care is to begin therapy at time of diagnosis

### •Recruitment and Consent

- ▶ Pre-screening via the electronic health record
- ▶ Study team member to approach patient at the beginning of the visit, before drug prescription
- ▶ Interested patients to be consented and provide a blood sample before departing the clinic

\* Fictional trial.

# The TERRIBLE Trial\*

## WHAT ACTUALLY HAPPENED



- ▶ IRB review twice
- ▶ Change in PI
- ▶ Inaccurate feasibility
- ▶ Flu season
- ▶ Screen fails
- ▶ Lost \$3,000/patient due to lack of enrollment and \$10,000 in startup costs
- ▶ Opened in 130 days
- ▶ Enrolled 0 patients

\* Fictional trial.

# Questions for after-action review

- ▶ What are the main process failures?
- ▶ What was the significance or impact of the failure?
- ▶ What caused the failure?
- ▶ What is a solution to the cause of the failure?
- ▶ Who will implement the solution?

# Questions for consideration

- ▶ What are your institution's global, recurring process failures?
- ▶ Who should be involved in the after-action review?
- ▶ Who has the ability and/or resources to implement solutions?
- ▶ How would you implement an after-action review process at your institution?

### After Action Review Worksheet

**Directions:** Develop ideas for a Corrective Action / Preventative Action (CAPA) plan. Describe each of the following:

- Process Failure: what went wrong?
- Significance/Impact: what was the result of the process failure? What did it impact?
- Root Cause: identify the root cause of the process failure
- Solution: identify a new checkpoint, process, or procedure that can be implemented to keep the process failure from recurring
- Personnel to Implement Solution: who will be responsible for implementing the solution?

Process Failure	Significance/Impact	Root Cause	Solution	Personnel to Implement Solution
				<input type="checkbox"/> Study manager <input type="checkbox"/> Principal Investigator <input type="checkbox"/> Clinical Research Coordinator <input type="checkbox"/> Finance Staff <input type="checkbox"/> Regulatory Staff <input type="checkbox"/> Institutional Official <input type="checkbox"/> Other:



# “Why does start-up take so long?”

- Slow CRO responses
- Legal or compliance questions
- Sponsor acquisition
- Inexperienced sponsor team
- New hardware
- New software
- Contracting with 3<sup>rd</sup> party suppliers
- Staff PTO
- Insufficient feasibility assessment
- Regulatory disagreements
- Medical device purchasing
- Lack of subject injury protection
- Investigator loss of interest
- IRB turnaround times
- Staff turnover
- Changes in workload
- Protocol amendments
- Unexpected study closure
- Budget stalemate
- Change of clinic location
- Pharmacy issues

